why choose us

First received: November 09, 2022

Clinical Trial: Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Lung Cancer

Study Type: INTERVENTIONAL


Official Title: Administration of T Cells Expressing a 2nd Generation GD2 Chimeric Antigen Receptor, IL-15, and iCaspase9 Safety Switch in Subjects With Lung Cancer

Brief Summary: This is a phase 1, single-center, open-label study that enrolls adult subjects with extensive stage lung cancer or stage IV non-small cell lung cancer that is platinum-refractory and received PD-1 and/or PD-L1 therapy.The purpose of this study is to test the safety of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the GD2 antigen (iC9-GD2.CAR.IL-15 T cells) in subjects with lung cancer.How much (dose) of the iC9-GD2.CAR.IL-15 T cells are safe to use without…

Read more